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ABSTRACT
Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against 
fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and 
abolished binding to IL-2 Rα. Here, we investigated the immunostimulatory properties of FAP-IL2v and its 
combination with programmed cell death protein 1 (PD-1) checkpoint inhibition, CD40 agonism, T cell 
bispecific and antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. The binding and 
immunostimulatory properties of FAP-IL2v were investigated in vitro and compared with FAP-IL2wt. 
Tumor targeting was investigated in tumor-bearing mice and in a rhesus monkey. The ability of FAP- 
IL2v to potentiate the efficacy of different immunotherapies was investigated in different xenograft and 
syngeneic murine tumor models. FAP-IL2v bound IL-2 Rβγ and FAP with high affinity in vitro, inducing 
dose-dependent proliferation of natural killer (NK) cells and CD4+/CD8+ T cells while being significantly 
less potent than FAP-IL2wt in activating immunosuppressive regulatory T cells (Tregs). T cells activated by 
FAP-IL2v were less sensitive to Fas-mediated apoptosis than those activated by FAP-IL2wt. Imaging 
studies demonstrated improved tumor targeting of FAP-IL2v compared to FAP-IL2wt. Furthermore, FAP- 
IL2v significantly enhanced the in vitro and in vivo activity of therapeutic antibodies that mediate 
antibody-dependent or T cell-dependent cellular cytotoxicity (TDCC) and of programmed death-ligand 
1 (PD-L1) checkpoint inhibition. The triple combination of FAP-IL2v with an anti-PD-L1 antibody and an 
agonistic CD40 antibody was most efficacious. These data indicate that FAP-IL2v is a potent immunocy-
tokine that potentiates the efficacy of different T- and NK-cell-based cancer immunotherapies.
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Interleukin-2 (IL-2) is a cytokine produced primarily by acti-
vated T cells that plays a critical function in the generation, 
differentiation, survival, and homeostasis of immune effector 
cells.1,2 IL-2 signaling is mediated by binding to the IL-2 
receptor (IL-2 R), which consists of up to three individual 
subunits, α (CD25), β (CD122), and γ (CD132).1 The low- 
affinity dimeric IL-2 Rβγ form is expressed on natural killer 
(NK) cells, monocytes, macrophages, and resting CD4+ and 
CD8+ T cells.1,2 The high-affinity trimeric IL-2 Rαβγ is tran-
siently induced on activated NK cells and CD4+ and CD8+ T 
cells. IL-2 functions to expand T cell populations in an auto-
crine fashion, differentiate antigen-activated CD4+/CD8+ T 
cells into effector T cell subsets, and activate NK cells.2 
Activation of innate and adaptive immune effector cells in 
this manner is the basis for using IL-2 to stimulate an anti- 
tumor response.3–5 However, to counteract autoimmunity, IL- 
2 also has immunosuppressive properties and is involved in 
peripheral immune tolerance mediated by CD4+ FOXP3+ reg-
ulatory T cells (Tregs), which constitutively express high levels 
of IL-2 Rα.2,6,7 Tregs suppress T cell activity, thereby compro-
mising anti-tumor immunity.8 IL-2 is also essential for activa-
tion-induced cell death (AICD) of activated T cells by 
upregulating the expression of Fas ligand and downregulating 
apoptosis inhibitors.9,10
High-dose IL-2 treatment (aldesleukin) is an effective ther-
apy for some patients with metastatic renal cell carcinoma and 
malignant melanoma.11–14 The therapeutic use of IL-2 as 
a cancer therapy is limited by its short half-life and severe 
cardiovascular events, as well as pulmonary, hepatic, gastro-
intestinal, neurological, and hematological toxicity.15 The sys-
temic and untargeted application of IL-2 may also compromise 
anti-tumor immunity by activating Tregs and inducing AICD. 
As such, there is a renewed interest in IL-2-based therapies that 
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are better tolerated and preferentially activate anti-tumor 
immune responses.16,17
Several attempts have been made to selectively deliver IL-2 
to the tumor environment by fusing IL-2 to antibodies directed 
against common tumor-associated antigens.18–26 These immu-
nocytokines have been shown to increase the circulating half- 
life of IL-220,25 with modest efficacy in early-phase clinical 
trials.19,24,26 However, no molecule has progressed beyond 
Phase 2 due to a number of limitations, including preferential 
affinity for IL-2 Rαβγ on peripheral immune cells and pulmon-
ary vascular endothelium that can override tumor targeting,25 
similar severe toxicity as free IL-2 therapy,22,26 and continued 
activation of Tregs due to the use of wild-type (wt) IL-2.18,26
Cergutuzumab amunaleukin (CEA-IL2v) is a novel immu-
nocytokine that comprises an IL-2 variant (IL2v) moiety fused 
to a carcinoembryonic antigen (CEA)-targeting antibody.27 
The IL2v part is engineered by structure-based mutation of 
key residues in the IL-2 Rα interface (F42A, Y45A, L72G) to 
abolish binding to IL-2 Rα while maintaining affinity for IL- 
2 Rβγ. These properties enable targeted delivery of immunos-
timulatory IL-2 to the site of the tumor without preferential 
activation of Tregs over immune effector cells. Abolished bind-
ing of CEA-IL2v to IL-2 Rα was confirmed in vitro.27 In vivo, 
CEA-IL2v treatment strongly expanded NK cell and CD8+ T 
cell populations in murine models of human cancer and was 
efficacious as single-agent, and potentiated the efficacy of anti-
body-dependent cellular cytotoxicity (ADCC)-competent anti-
bodies and an anti-programmed death-ligand 1 (PD-L1) 
checkpoint inhibitor.27
Fibroblast activation protein α (FAP) is a dimeric Type II 
transmembrane glycoprotein with proteolytic activity.28,29 FAP 
is expressed scarcely in normal, healthy adult tissues, but is 
highly expressed on the surface of cancer-associated fibroblasts 
and pericytes in >90% of human epithelial malignancies.28–33 
The high and restricted expression on reactive stroma in the 
tumor microenvironment makes FAP a promising target for 
tumor treatment. The basic design of simlukafusp alfa (FAP- 
IL2v) is shown in Figure 1. FAP-IL2v contains the IL2v mutein 
and a (G4S)3 connector fused to the high-affinity FAP human 
IgG1 antibody 4B9 that was generated and affinity matured by 
phage display. FcγR binding is abolished by the introduction of 
P329G LALA mutations whereas binding to the neonatal Fc 
receptor (FcRn) is maintained to retain IgG-like antibody half- 
life.34
FAP-IL2v is designed to increase the pool of activated 
immune effector cells and is intended to be a combination 
partner to enhance the efficacy of cancer immunotherapies 
that work through the patient’s immune effector cells. In this 
study, we show that FAP-IL2v targets the site of the tumor and 
activates NK cells and CD4+/CD8+ T cells, without preferen-
tially activating Tregs, leading to up-regulation of IL-2 Rα 
(CD25) and CD69 and phosphorylation of the IL-2 receptor 
signaling molecule STAT5 (signal transducers and activators of 
transcription 5). Furthermore, we demonstrate that increasing 
the pool of activated NK cells potentiates the efficacy of ADCC- 
competent antibodies while increasing the pool of T cells 
potentiates the efficacy of T cell bispecific antibodies. 
Furthermore, preexisting T cell responses are enhanced by 
combining FAP-IL2v with checkpoint inhibitors (e.g., PD-L1) 
and CD40 agonism in a variety of xenograft and syngeneic 
murine tumor models.
Results
FAP-IL2v binds FAP and IL-2Rβγ in vitro with high affinity, 
but not IL-2Rα
The IL2v portion of FAP-IL2v was designed not to bind to IL- 
2R, but to retain the affinity and functional activity for the 
intermediate-affinity dimeric IL-2Rβγ. Surface plasmon reso-
nance experiments demonstrated that human IL-2Rα binds to 
human IL2wt bound to the IL-2Rβγ complex, but not to IL2v 
bound to IL-2Rβγ complex (Supplementary Figure 1a). These 
data were confirmed in Tag-lite competition binding assays, 
which showed that IL2wt bound to IL-2R better than IL2v 
bound IL-2R on cells expressing IL-2R containing all three 
chains (IL-2Rα, β and γ), whereas on cells expressing IL-2R 
containing only IL-2Rβ- and γ-chains (no IL-2Rα-chain), the 
Figure 1. Structure of FAP-IL2v. Abbreviations: AICD, activation−induced cell death; FAP, fibroblast activation protein-α; FAP-IL2v, FAP-targeted interleukin 2 variant 
(IL2v) immunocytokine; FcγR, Fc gamma receptor; FcRn, neonatal Fc receptor; IL-2Rβγ, interleukin 2 receptor β and γ; KiH, “knobs-into-holes” technology; NK, natural 
killer (cell); Tregs, regulatory T cells.
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binding of IL2v and IL2wt to IL-2R was similar (right panel) 
(Supplementary Figure 1b).
Supplementary Table 1 shows the respective affinities of 
FAP-IL2v to human, mouse and cynomolgus monkey IL- 
2Rα, IL-2Rβγ, and FAP. A murinized version of FAP-IL2v 
(muFAP-muIL2v) was generated for use in fully immunocom-
petent mice to minimize potential anti-drug antibody forma-
tion; this variant showed comparable binding properties to 
FAP-IL2v. The ability of FAP-IL2v to bind simultaneously to 
FAP and the IL-2 receptor was assessed in a “sandwich” bind-
ing assay on FAP expressing fibroblasts. Binding of FAP-IL2v 
to FAP was detected with recombinant IL-2Rβγ-Fc heterodi-
mer, confirming the ability of bispecific binding 
(Supplementary Figure 2).
FAP-IL2v activates CD4+/CD8+ T cells and NK cells in vitro, 
but not preferentially Tregs
FAP-IL2v induced a dose-dependent proliferation of resting NK 
cells and resting and activated CD4+ and CD8+ T cells within 
peripheral blood mononuclear cells (PBMCs) derived from 
healthy volunteers (Supplementary Figures 3 and 4 and 
Supplementary Table 2). In general, NK cells responded 
promptly to FAP-IL2v treatment, and most cells underwent 
proliferation after 5 days of treatment. Similar to NK cells, 
most CD8+ T cells underwent proliferation after 5 days of 
treatment, whereas CD4+ T cells responded more slowly, with 
only a proportion of cells proliferating after the same period. 
Compared with NK cells, higher concentrations of FAP-IL2v 
were required to stimulate resting T cells. Activation of IL-2R 
signaling in immune cells was demonstrated by a dose- 
dependent increase of STAT5 phosphorylation (Figure 2a and 
Supplementary Table 3). Treatment with FAP-IL2v activated 
CD4+ T cells, CD8+ T cells, and NK cells to a similar extent as 
treatment with FAP-IL2wt. Importantly, FAP-IL2v was signifi-
cantly less potent than FAP-IL2wt in activating Tregs, which 
express high levels of IL-2Rα. Activation of CD4+ and CD8+ T 
cells was also demonstrated by the upregulation of the early 
activation marker CD69 and late activation marker IL-2Rα 
(CD25) (Supplementary Figure 5). FAP-IL2v and FAP-IL2wt 
induced a similar upregulation of CD69, whereas upregulation 
of IL-2Rα was much stronger following treatment with FAP- 
IL2v. Notably, T cells activated by FAP-IL2v were less sensitive 
to Fas-mediated apoptosis (AICD) than T cells activated by 
FAP-IL2wt or aldesleukin (Supplementary Figure 6).
FAP-IL2v enhances cetuximab-mediated ADCC and CEA- 
TCB-mediated T-cell-dependent cellular cytotoxicity (TDCC) 
in vitro
Cell-killing assays were used to determine if the activating 
effect of FAP-IL2v on NK cells and CD4+/CD8+ T cells could 
enhance cell killing by antibodies that mediate ADCC or 
TDCC. LS174T colon cancer cell killing with FAP-IL2v alone 
was limited, but enhanced considerably when combined with 
the ADCC-competent antibody cetuximab (Figure 2b). NK cell 
activation (as measured by upregulation of IL-2Rα and CD69) 
was also enhanced considerably with the combination com-
pared with FAP-IL2v alone. Similarly, CEA-TCB enhanced the 
FAP-IL2v-mediated killing of MKN45 gastric cancer cells com-
pared with FAP-IL2v treatment alone (Figure 2c). This was 
accompanied by increased activation of T cells and cytokine 
release when combining FAP-IL2v with CEA-TCB. 
Interestingly, a drop-off in IL-8 levels was observed at higher 
doses of FAP-IL2v in combination with cetuximab (Figure 2c). 
The reason for this is unknown.
FAP-IL2v pharmacokinetics and pharmacodynamics in the 
mouse
Exposure of human FAP-IL2v in CD-1 mice was dose propor-
tional (Supplementary Table 4). Dose normalized AUC0–16h 
ranged from 479 to 557 μg · h/mL following intravenous (IV) 
dosing (1–4 mg/kg) FAP-IL2v clearance was 38.7–46.8 mL/d/ 
kg, which is faster than a normal IgG, but this result can be 
expected because of the target-mediated drug disposition fol-
lowing IL2v binding to IL-2 receptors on T cells and NK cells, 
as well as binding to low levels of FAP in normal tissues.35 
When tumor-free severe combined immunodeficiency (SCID) 
beige mice were administered a single IV dose of 0.3 mg/kg 
human FAP-IL2v or human FAP-IL2wt, it became obvious 
that FAP-IL2wt is much more rapidly cleared than FAP-IL2v 
through CD25 mediated drug disposition (Supplementary 
Figure 7b). Importantly, a dose-dependent exposure could be 
observed in C57BL/6 mice treated with 0.5, 1.0, or 2.0 mg/kg 
FAP-IL2v (Supplementary Figure 7b).
Blood exposure of FAP-IL2v in tumor-free C57BL/6 mice 
and in mice bearing Panc02-H7-Fluc subcutaneous tumors is 
shown in Supplementary Figure 8a. Lower levels of peripheral 
activation were observed in tumor-bearing mice compared 
with tumor-free mice, as seen by reduced increases of CD3 
and CD8 T cells, but not CD4 T cells, in the plasma 3 days after 
administration of FAP-IL2v (Supplementary Figure 8b). FAP- 
targeted IL2v accumulation in the tumors induced higher levels 
of CD3 cells, CD8 T cells, NKp46 NK cells, and CD68-positive 
macrophages 3 days post-treatment compared with the vehicle 
group (Supplementary Figure 8 c).
FAP-IL2v targets the tumor in vivo
Biodistribution in mice
Single-photon emission computed tomography (SPECT)/com-
puted tomography (CT) imaging and biodistribution studies 
were performed in immunocompetent BALB/c mice bearing 
syngeneic Renca renal cancer carcinoma tumors in the right 
kidney that showed a relatively high number of FAP-positive 
fibroblasts in the tumor stroma by immunohistochemistry 
(Supplementary Figure 9). The highest tumor uptake of 111In- 
labeled antibodies injected IV was observed with FAP-IgG 
(17.9 ± 1.1%ID/g of tissue; Figure 3a). Tumor uptake observed 
with FAP-IL2v (13.8 ± 1.3%ID/g) was higher than that with 
FAP-IL2wt (11.5 ± 0.8%ID/g; p = .04). As observed in the 
SPECT/CT images, some accumulation of FAP-IL2v was 
observed in the lymphoid tissues of the spleen, but this was 
significantly lower compared with FAP-IL2wt (10.8 ± 0.9%ID/ 
g vs 38.0 ± 3.6%ID/g, respectively; p = .0002). FAP-IL2wt 
mainly accumulated in the spleen and in various lymph 
nodes. Tumor uptake of untargeted DP47-IL2v (5.3 ± 0.8% 
ID/g) was twofold to threefold lower than that of FAP-targeted 
antibodies. As DP47-IL2v has lower clearance than FAP-IL2v 
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Figure 2. Activation of CD4+/CD8+ T cells and NK cells and cell killing in vitro. (a) Phosphorylation of STAT5 on CD4 T cells (CD3+ CD4+ CD25-), NK cells (CD3-CD56+), 
CD8 T cells (CD3+ CD8+ CD25-), and Tregs (CD4+ CD25+ FOXP3+) 20 min after treatment with different IL2/IL2v-containing constructs. (b) Tumor cell lysis and 
upregulation of NK cell activation markers following co-culture of LS174T colon cancer cells, GM05389 FAP-expressing fibroblasts, and human PBMCs with FAP-IL2v 
alone, cetuximab (1000 ng/mL fixed concentration) alone or the combination of FAP-IL2v and cetuximab, for 48 hours. (c) Tumor cell lysis, IL-2Rα (CD25) upregulation 
on CD8+ T cells, and cytokine release upon treatment of MKN45 cells with FAP-IL2v alone or in combination with CEA-TCB (0.2 nM fixed concentration) in the presence 
of PBMCs. Data are mean and standard deviation of triplicate experiments. Abbreviations: CEA-TCB; carcinoembryonic antigen T-cell bispecific antibody; FAP-IL2v, 
fibroblast activation protein-α -targeted interleukin 2 variant (IL2v) immunocytokine (the lead molecule); FAP-IL2wt, the lead molecule containing wild-type IL-2 instead 
of IL2v; MFI, mean fluorescent intensity; NK, natural killer (cell); (p)STAT5, (phosphorylated) signal transducer and activator of transcription 5A; PBMCs, peripheral blood 
mononuclear cells; Tregs, regulatory T cells.
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(data not shown), the lower uptake of DP47-IL2v is not related 
to faster clearance. In addition, enlargement of the spleen was 
observed in these mice. The diffuse signal seen in other organs 
of DP47-IL2v-treated mice likely represents binding to 
immune cells in the blood pool in these mice and the longer 
half-life of DP47-IL2v.
There was a trend for dose dependence in spleen accumula-
tion of FAP-IL2v; 0.1 mg/kg had the highest spleen accumula-
tion, followed by 0.3 mg/kg and 1 mg/kg, suggestive of 
a saturable IL-2R sink in the spleen (Supplementary Figure 
10). Tumor accumulations were identical between 0.3 mg/kg 
and 1 mg/kg.
Figure 3. Biodistribution in animal models. (a) SPECT/CT imaging of 111In-labeled FAP-IgG, FAP-IL2v, FAP-IL2wt and DP47-IL2v in immunocompetent BALB/c mice 
(n = 3 per treatment) bearing renal carcinoma in the right kidney. Imaging was performed 3 days after IV injection of 0.3 μg 111In-labeled antibodies co-injected with 
25 μg of corresponding unlabeled antibodies. (b) FDG-PET/CT axial view imaging of 89Zr-FAP-IL2v localization in lesions of a single rhesus monkey with breast 
carcinoma. The monkey was treated with 0.5 mg/kg of FAP-IL2v IV mixed with tracer amounts of 89Zr-labeled FAP-IL2v. PET scans were performed on the day of 
administration and 3 days (67 hours) and 6 days (154 hours) after IV injection. On-treatment biopsy was performed on Day 3 following the PET scan. Abbreviations: 
FAP, fibroblast activation protein-α; FDG-PET/CT, fluorodeoxyglucose-positron emission tomography/computed tomography; IL2v, interleukin 2 variant; IL2wt, 
interleukin 2 wild-type; 111In, indium-111; PET, positron emission tomography; SPECT/CT, single-photon emission computed tomography/computed tomography; 
89Zr, zirconium-89.
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Biodistribution in a rhesus monkey with breast carcinoma
Positron-emission tomography (PET) imaging in a tumor- 
bearing rhesus monkey was conducted to demonstrate the 
superior tumor targeting of FAP-IL2v in a fully immunocom-
petent and relevant animal model. FAP expression in tumor 
stroma was confirmed by immunohistochemistry 
(Supplementary Figure 11a). Three fluorodeoxyglucose 
(FDG)-avid lesions were identified on PET scans. Based on 
postmortem histology, two-third FDG-avid lesions were con-
firmed as tumor lesions, while the FDG-avid lesion in the 
axillary lymph node was most like an inflammatory lesion. 
ImmunoPET scans showed that 89Zr-FAP-IL2v selectively 
accumulated in all three lesions identified on FDG PET scans 
(Figures 3b; 0.04–0.06%ID/mL). 89Zr-FAP-IL2v was primarily 
excreted through the hepatobiliary pathway, with minimal 
uptake in the lungs, spleen, and lymphoid tissues 
(Supplementary Figure 11b-d). Analysis of tumor biopsies 
revealed immune cell infiltration (Supplementary Figure 11e). 
Transient lymphocytosis and peripheral expansion of immune 
cells was observed (Supplementary Table 5) alongside an 
increase of CD25+ cells (indicative of lymphocyte activation 
in T and NK cells) and the percentage of CD3+, CD4+, CD25 
+, and FoxP3+ cells at Day 4 (Supplementary Table 6).
FAP-IL2v is efficacious in combination with therapeutic 
antibodies in murine models of human cancer
Combination with ADCC-competent antibodies
muFAP-muIL2v potentiated the efficacy of an ADCC- 
competent antibody against human epidermal growth factor 
receptor 2 (HER2) in BALB-neuT genetically engineered mice 
that spontaneously develop breast tumors because of the mam-
mary-specific expression of a constitutively active variant of 
ratHER2 (neuT). In this model, single-agent muFAP-muIL2v 
(2 mg/kg) or an equivalent dose of untargeted muDP47- 
muIL2v (0.7 mg/kg) was given once weekly for 5 weeks, start-
ing on week 19/21 after birth when mammary tumors were 
already measurable (average size 200 mm3). Single-agent 
muFAP-muIL2v did not exhibit therapeutic efficacy compared 
with the vehicle control group (Figure 4a). Only anti-ratHER2 
Figure 4. Efficacy in combination with an ADCC-competent antibody. (a) Targeted muFAP-muIL2v (2 mg/kg), untargeted muDP47-muIL2v (0.7 mg/kg), and anti-ratHER2 
muIgG2a (20 mg/kg) were administered as single agents and in combination in the BALB-neuT genetically engineered mouse mammary tumor model (n = 6 per group). 
Treatments were given IV once weekly for 5 weeks starting at Week 19 or Week 21. (b-c) Mammary fat pad tumors from these mice were harvested 5 days after the last 
treatment and analyzed by immunohistochemistry for CD3 T cells, NK cells, and CD68-expressing cells. Representative immunohistochemistry staining images are 
shown in Supplementary Figure 12 and 13. * p < .05; ** p < .01; *** p < .001 vs vehicle control (unpaired t-test). Abbreviations: EGFR, epidermal growth-factor receptor; 
FAP-IL2v, fibroblast activation protein-α -targeted interleukin 2 variant (IL2v) immunocytokine (the lead molecule); HER2, human epidermal growth factor 2; hu 
humanized; mu, murinized; muFAP-muIL2v, murinized version of the lead molecule; muDP47-muIL2v, murinized untargeted interleukin 2 variant immunocytokine SC, 
subcutaneous; SCID, severe combined immunodeficient.
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muIgG2a significantly prolonged survival as a single-agent 
therapy compared with vehicle alone, with a median survival 
of 90 days (p = .0011). This effect appeared to be more than 
additive: the combination of anti-ratHER2 and muFAP- 
muIL2v significantly extended the median survival to 
114 days compared with single-agent muFAP-muIL2v 
(p = .0016) and single-agent anti-ratHER2 (p = .042). Anti- 
ratHER2 combined with untargeted muDP47-muIL2v was not 
superior to single-agent anti-ratHER2 (p = .08). This efficacy 
was accompanied by a significant increase in tumor-infiltrating 
CD3 T cells, NK cells, and CD68-positive cells (Figure 4b-d 
and Supplementary Figure 12). The highest increase of NK 
cells and activated macrophages was observed in the combina-
tion group. The kinetics of baseline immune infiltration in 
BALB-neuT mouse model are shown in Supplementary 
Figure 13.
Similar efficacy was demonstrated in combination with 
cetuximab in the lung orthotopic xenograft A549 model in 
huCD16-transgenic SCID mice (which express the human 
FcγRIIIα receptor on NK cells and the homologous 
muFcγRIV receptor on macrophages/monocytes; 
Supplementary Figure 14a) and in the syngeneic B16- 
huEGFR lung metastatic model in fully immunocompetent 
C57BL/6 huEGFR huCD16-transgenic mice (Supplementary 
Figure 14b). Finally, combining FAP-IL2v (1 mg/kg QW for 
5 weeks) with the ADCC-competent anti-CD20 antibody obi-
nutuzumab (25 mg/kg QW for 5 weeks) in the subcutaneous 
WSU-DLCL2 diffuse large B-cell lymphoma xenograft model 
in SCID/huCD16-transgenic mice achieved greater tumor con-
trol than either agent given as monotherapy (Supplementary 
Figure 14 c). A reduction in tumor volume of 28% (p = .0303), 
63% (p < .0001), and 98% (p < .0001) in tumor growth was 
observed in the FAP-IL2v, obinutuzumab, and the combina-
tion groups, respectively, compared with controls at study 
Day 39.
Combination with TDCC-competent antibody
muFAP-muIL2v also demonstrated synergy with a murinized 
T cell bispecific antibody targeting CEA on tumor cells and 
CD3 on T cells (muCEA-TCB). Median survival in Panc02- 
huCEA-transgenic C57BL/6 mice was significantly longer with 
single-agent muFAP-muIL2v (2 mg/kg IV QW; 38.5 days; 
p = .0231) and single-agent muCEA-TCB (2.5 mg/kg IV 
weekly; 41.5 days; p = .0003) compared with vehicle alone 
(28 days; Figure 5). However, combination therapy with 
muFAP-muIL2v plus muCEA-TCB achieved significantly 
longer median survival (61 days) compared with single-agent 
muFAP-muIL2v (p < .0001), muCEA-TCB (p = .0033), and 
vehicle (p < .0001).
Combination with PD-L1 checkpoint inhibition
The combination of FAP-IL2v with checkpoint inhibitor anti- 
PD-L1 was tested using muFAP-muIL2v and anti-muPD-L1 (a 
murine IgG2a surrogate antibody against murine PD-L1) in 
a Panc02 pancreatic orthotopic syngeneic model in fully 
immunocompetent C57BL/6 mice. This model is characterized 
by inflamed tumors with preexisting antigen-specific T cells. 
Panc02 cells express PD-L1 and are susceptible to PD-L1- 
targeting therapies.36,37 Median survival with muFAP-muIL2v 
(2 mg/kg) administered with anti-muPD-L1 (10 mg/kg) given 
via intraperitoneal (IP) injection weekly for 5 weeks was sig-
nificantly longer compared with the respective single agents 
(p = .0003 vs. muFAP-muIL2v and p = .05 vs. anti-muPD-L1; 
Figure 6a).
Triple combination with PD-L1/CD40 antibodies
FAP-IL2v also strongly enhanced the activity of an agonistic 
CD40 antibody (anti-muCD40; 10 mg/kg given IP once at 
Day 7) in the Panc02 model (Figure 6b). Median survival was 
40 days with muFAP-IL2v monotherapy, 45 days with anti- 
muCD40 monotherapy, and 93 days (p = .0005 vs vehicle con-
trol) with the combination. The triplet of muFAP-muIL2v, anti- 
muPD-L1, and anti-muCD40 achieved the greatest efficacy 
(median survival not reached vs 35 days with vehicle control, 
p < .0001). Long-term surviving animals from this study who 
received the triplet or doublet combinations were protected from 
tumor re-challenge with Panc02 cells (Figure 6c).
Discussion
To increase the benefit–risk ratio of the currently available 
systemic cytokine therapy, it is desirable to develop novel 
immunocytokines that combine antibodies with superior 
tumor-targeting ability and cytokines with broad-based 
immune-modulatory activities to effectively mobilize or sus-
tain anti-tumor immune responses at the tumor site. Various 
approaches are currently in development to achieve immunos-
timulation through IL-2 without activating suppressive Tregs, 
including NKTR-214 (bempegaldesleukin, Nektar 
Therapeutics) and ALT-803 (Altor BioScience). The prodrug 
Figure 5. Efficacy in combination with a TDCC-competent antibody. muFAP- 
muIL2v (2 mg/kg IV once weekly) was administered in combination with the 
TDCC-competent antibody muCEA-TCB (2.5 mg/kg IV twice weekly) in the 
inflamed orthotopic Panc02-CEA model in CEA transgenic C57BL/6 mice (n = 8 
mice per group). Treatments (four in total) started 7 days after tumor cell 
injection. Abbreviations: muCEA-TCB, murinized carcinoembryonic antigen-T 
cell bispecific; muFAP-muIL2v, murinized version of fibroblast activation pro-
tein-α-targeted interleukin 2 variant immunocytokine; TDCC, T cell-dependent 
cellular cytotoxicity.
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NKTR-214 is a modified form of IL-2 conjugated to releasable 
polyethylene glycol chains that mask the part of IL-2 that 
interacts with the IL-2Rα subunit to reduce activation of 
Tregs.38 Preclinical data show that NKTR-214 treatment 
results in rapid expansion of effector T cells and is well toler-
ated in non-human primates.38 ALT-803 is a supercomplex of 
modified IL-15 and IL-15Rα fused to an IgG1 Fc. IL-15 stimu-
lates NK cells and effector T cells, but unlike IL-2, IL-15 does 
not stimulate Tregs. Initial clinical data show that ALT-803 is 
well tolerated and leads to dose-dependent increases in CD8 
+ T cells and NK cells.39,40
In contrast to these engineered IL-2Rβγ agonists that act in 
a “untargeted” manner, FAP-IL2v is a novel immunocytokine 
designed to bind FAP on tumor stroma cells to deliver an 
immunostimulatory IL-2 variant to the tumor site without 
preferential activation of immunosuppressive Tregs. Here, we 
investigated the pharmacodynamic and pharmacokinetic 
properties of FAP-IL2v in vitro and in vivo and show how the 
immunostimulatory properties of FAP-IL2v can potentiate the 
efficacy of a variety of cancer immunotherapies.
FAP-IL2v is a species of cross-reactive and bound human, 
mouse, rhesus, and cynomolgus monkey FAP and IL-2Rβγ, but 
not IL-2α, with high affinity in vitro. FAP-IL2v was signifi-
cantly less potent than FAP-IL2wt in activating immunosup-
pressive Tregs, which express high levels of IL-2Rα. Because 
the binding to IL-2Rβγ was retained, FAP-IL2v was able to 
activate NK cells and CD4+/CD8+ T cells in vitro, as demon-
strated by up-regulation of classical activation markers, such as 
CD69 and IL-2Rα (CD25), and induction of proliferation and 
phosphorylation of the IL-2R signaling maker STAT5, in 
a dose-dependent manner that did not differ from that of FAP- 
IL2wt. This is expected to translate into significantly lower 
expansion of Tregs than immune effector cells in vivo, which 
is desirable when attempting to restore immune cell activation 
Figure 6. Efficacy in combination with PD-L1 checkpoint inhibition. (a) Efficacy of muFAP-muIL2v (2 mg/kg IP) and anti-muPD-L1 (10 mg/kg IP) as single agents and in 
combination given once weekly for 5 weeks starting on Day 7 in the Panc02 pancreatic orthotopic syngeneic model in C57BL/6 mice (n = 10 mice per group). (b) Efficacy 
in the same mouse model with the addition of muCD40 (10 mg/kg IP given once on Day 7) as single agent and in combination with muFAP-muIL2v (2 mg/kg IP) and 
anti-muPD-L1 (10 mg/kg IP) given once weekly for 3 weeks (n = 6–8 mice per group). (c) Tumor growth in surviving mice from experiments shown in part (b) that were 
re-challenged subcutaneously with Panc02 cells (5 × 105) on Day 121 (Day 0 in Figure 6c). No additional antibody therapy was given in these experiments. A new group 
of vehicle-only treated mice was used for comparison in this experiment. Abbreviations: IP, intraperitoneally; muFAP-muIL2v, murinized version of fibroblast activation 
protein-α-targeted interleukin 2 variant immunocytokine; muPD-L1, murinized anti-PD-L1 antibody; muCD40, murinized agonistic CD40 antibody.
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and attenuate local tumor immunosuppression. These data are 
consistent with the proposed mode of action of FAP-IL2v, 
which was engineered to abolish binding to IL-2Rα without 
affecting binding to IL-2Rβγ on immune effector cells. The 
binding properties of the IL2v part of FAP-IL2v are consistent 
with those of the IL2v part of CEA-IL2v.27
Strongly activated T cells upregulate Fas and are sensitive to 
Fas-mediated apoptosis.41 This was observed with aldesleukin 
treatment and in cells treated with FAP-IL2wt. FAP-IL2v- 
treated T cells, however, were considerably less sensitive to Fas- 
mediated apoptosis, suggesting that IL2v-stimulated T cells are 
more resistant to activation-induced cell death.
Data from in vivo imaging studies on tumor-bearing immu-
nocompetent mice and a rhesus monkey with breast carcinoma 
demonstrated that FAP-IL2v preferentially localized within 
tumor tissue over lymphoid and other tissues. While some 
accumulation was seen in the spleen in mice, splenic accumu-
lation was not observed in the rhesus monkey, which likely 
reflects species differences in the response to FAP-IL2v. High 
liver uptake of FAP-IL2v was observed in the monkey, but not 
in mice. This different localization of FAP-IL2v between mice 
and monkeys may also be explained by the lower dose admi-
nistered to the monkey as compared to the dose applied to 
mice, and potentially the older age of the monkey and generally 
lower pharmacodynamic response in monkeys versus mice, for 
example, regarding absolute increase in T cell numbers.
The fact that FAP-IL2wt showed more distribution in the 
spleen than FAP-IL2v indicates that the distribution in the 
wild-type setting is driven by binding to IL-2R; however, with 
lower affinity to the IL-2R complex, the anti-Fap domain takes 
over the targeting. Tumor localization of FAP-IL2v is consis-
tent with FAP binding on tumor stromal cells, the limited 
expression of FAP in healthy tissues, and the lack of IL-2Rα 
binding on immune cells. The lack of IL-2Rα binding by FAP- 
IL2v is expected to lead to the relative absence of a peripheral 
IL-2Rα sink on immune cells. This will likely overcome the 
poor tumor targeting properties seen with conventional wild- 
type IL-2-based immunocytokines.25 However, it should be 
noted that FAP-IL2v still has functional activity on immune 
cells in the peripheral blood and lymphoid tissues through its 
monovalent and intermediate affinity to IL-2Rβγ. These obser-
vations are supported by pharmacokinetic studies that showed 
an approximately twofold reduction in clearance of an untar-
geted DP47-IL2v immunocytokine when compared with the 
analogous wild-type DP47-IL2wt immunocytokine, confirm-
ing that the introduction of the IL2v indeed reduces the IL-2Rα 
-mediated clearance and results in a longer half-life.42
Biodistribution studies in the breast cancer-bearing rhesus 
monkey confirmed that FAP-IL2v targets the tumor in vivo 
and, importantly, showed that uptake of FAP-IL2v in lung 
tissue was minimal (lung metastases were not present in this 
animal). No signs of pulmonary injury were seen in this ani-
mal. Pulmonary edema is a key and severe side effect of IL-2 
therapy and is mediated by the direct binding of IL-2 to IL-2Rα 
on lung endothelial cells.16 The lack of binding of FAP-IL2v to 
IL-2Rα and its limited distribution to lung tissue should trans-
late into reduced pulmonary toxicity compared with other IL- 
2-based therapies. Biodistribution studies in the rhesus mon-
key ran for 6 days, which is sufficient to ensure that the 
observed targeting is specific. The murine biodistribution stu-
dies were limited to 3 days, which may not be sufficient time for 
complete distribution and targeting. This limitation was due to 
the aggressive tumor growth in the murine models and the 
need for recurrent anesthesia/imaging-related procedures; 
later, scans were not considered practical to minimize the 
discomfort to the mice.
A possible clinical application of FAP-IL2v would be in 
combination with ADCC-competent antibodies of the IgG1 
isotype to enhance their role in ADCC. Our data showed that 
FAP-IL2v increased the pool of activated NK cells in vitro, 
which significantly potentiated the ADCC activity of cetuxi-
mab in cell killing assays. This translated into strongly 
enhanced anti-tumor efficacy mediated by ADCC-competent 
or -enhanced antibodies in the lung orthotopic xenograft A549 
model in huCD16 transgenic SCID mice, in the genetically 
engineered BALB-neuT mouse model developing spontaneous 
breast tumors, in the syngeneic lung metastatic B16-EGFR 
model in fully immunocompetent C57BL/6 huEGFR huCD16 
transgenic mice, and in the aggressive non-Hodgkin’s lym-
phoma model WSU-DLCL2 in human CD16 transgenic 
SCID mice. While FAP-IL2v (or the murine equivalent 
muFAP-muIL2v) monotherapy significantly extended median 
survival compared with vehicle alone in some models, combi-
nation therapy with FAP-IL2v significantly potentiated the 
efficacy of all tested ADCC-competent antibodies (cetuximab, 
a ratHER2-specific antibody, and obinutuzumab).
FAP-IL2v also potentiated the efficacy of immunotherapies 
that work through T cells. FAP-IL2v is synergized with the 
T cell bispecific antibody CEA-TCB in vitro, which translated 
into enhanced efficacy in the inflamed syngeneic orthotopic 
pancreatic Panc02 model in human CEA transgenic C57BL/6 
mice vs either treatment alone. CEA-TCB binds CEA on tumor 
cells and the CD3ε chain within the TCR complex on T cells 
and triggers an increase in tumor-infiltrating T cells, T cell 
activation, secretion of cytotoxic granules, and tumor cell lysis 
and regression.43,44
FAP-IL2v was also shown to synergize with a therapeutic 
antibody targeting the PD-L1 checkpoint inhibitor and an 
agonistic CD40 antibody. Most notably, the triple combination 
of FAP-IL2v with PD-L1 checkpoint inhibition and CD40 
agonism resulted in long-term survival of the majority of 
animals, and this therapeutic effect persisted when surviving 
animals were re-challenged with tumor cells but without 
further administration of therapeutic antibodies. In this set-
ting, we believe that FAP-IL2v in combination with the check-
point inhibitor PD-L1 strongly enhances the activation of 
preexisting antigen-specific T cells in the tumor, whereas the 
combination with the CD40 agonistic antibody can further 
enhance the generation of a long-lasting anti-tumor efficacy 
in the majority of animals.
Taken together, these data indicate that FAP-IL2v is 
a versatile combination partner for a diverse range of cancer 
immunotherapies including ADCC-competent antibodies, 
T cell bispecific antibodies, and checkpoint inhibitors. The 
immunostimulatory properties of FAP-IL2v may be particu-
larly useful in combination with PD-L1 checkpoint inhibition 
and/or CD40 agonism for the treatment of inflamed tumors, 
but also in poorly inflamed tumors when combined with 
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ADCC- or TDCC-mediating antibodies. Furthermore, our 
data show that FAP-IL2v overcomes many of the limitations 
of aldesleukin and other IL-2–based immunocytokines, by 
superior tumor targeting, lack of preferential activation of 
Tregs, and lack of binding to pulmonary epithelium. FAP- 
IL2v is currently in Phase 1b/2 clinical development as 
a monotherapy and in combination with trastuzumab and 
cetuximab (NCT02627274), atezolizumab (anti-PD-L1; 
NCT03386721), and atezolizumab plus bevacizumab 
(NCT03063762). Study NCT02627274 in patients with meta-
static solid tumors has identified a recommended dose and 
schedule for FAP-IL2v of 20 mg IV once weekly.45 Rapid 
expansion of CD8 cells and NK cells, but not Tregs, was 
observed in patients treated at this dose. Three long-lasting 
(>6 months) objective responses with FAP-IL2v monotherapy 
were observed across the dose escalation range (in patients 
with head and neck cancer, penile squamous cell carcinoma, 
and checkpoint inhibitor-resistant malignant melanoma). 
Tumor shrinkage occurred in four melanoma patients. The 
most adverse events were Grade 1/2 and included (>30%) 
pyrexia, infusion-related reactions, fatigue/asthenia, nausea, 
diarrhea, decreased appetite and elevated aspartate and/or ala-
nine transaminase.45 At the dose range applied to mice in this 
study, we did not observe any clinical signs of toxicity due to 
FAP-IL2v, but, in general, mice are less sensitive to IL-2 
mediated toxicities.
In conclusion, FAP-IL2v is a novel and potent immunocy-
tokine that targets the site of the tumor and activates immu-
nostimulatory CD4+/CD8+ T cells and NK cells without 
preferentially activating immunosuppressive Tregs. It is 
a versatile combination partner for various cancer immu-
notherapies and has the potential to be developed for clinical 
use in combination with checkpoint inhibitors, T cell bispecific 
antibodies, ADCC-mediating antibodies, and other novel 
immunomodulatory agents.
Materials and methods
The cell lines used in these studies and their origin are 
described in the supplementary methods, along with details 
of the surface plasmon resonance experiments, sandwich bind-
ing assays, and pharmacokinetic experiments.
Immunocytokines and antibodies
For in vitro studies, studies in immunodeficient mice, and 
short-term studies in immunocompetent mice, human IgG1- 
based immunocytokines (FAP-IL2v and FAP-IL2wt) were 
used. To reduce the risk of immunogenicity and loss of expo-
sure in long-term pharmacodynamic studies in fully immuno-
competent C57BL/6 mice, murinized surrogate 
immunocytokines (muFAP-muIL2v, muDP47-muIL2v) were 
used. These surrogates were based on the respective human-
(ized) variable regions and mouse IgG1 constant regions with 
DAPG mutations to abolish FcγR and C1q interaction and 
a mutated murine IL-2 variant carrying homologous mutations 
to abolish muIL-2Rα binding. The design details are given in 
Supplementary Tables 7 and 8. All immunocytokines were 
produced by transient production using HEK293 or stable 
Chinese hamster ovary clones followed by purification using 
Protein A affinity chromatography and size-exclusion/ion- 
exchange chromatography. STAT5 phosphorylation, prolifera-
tion, and AICD with FAP-IL2v are described elsewhere.27 The 
anti-ratHER2 muIgG2a and a murinized version of cetuximab 
(based on the clone C225) were generated in house. 
Commercial cetuximab was obtained from Merck and obinu-
tuzumab was obtained from Roche Pharmaceuticals.
In vitro combination with ADCC-competent antibodies
A total of 30,000 LS174T human colon tumor cells and 5000 
GM05389 human fibroblasts were seeded into 96-well flat- 
bottom plates and co-cultured with 300,000 human PBMCs 
at an effector-to-target cell ratio (E:T) of 10:1. Cells were 
incubated with increasing concentrations of FAP-IL2v with 
or without 1000 ng/mL of the anti- epidermal growth-factor 
receptor (EGFR) antibody cetuximab. Cytotoxicity was deter-
mined after 24 hours by measuring lactate dehydrogenase 
(LDH) release into the supernatant (Roche Applied Science). 
PBMCs were collected from the supernatant and stained with 
CD3 BUV359 (clone UCHT1, BD Bioscience), CD56 BV711 
(clone HCD56, BioLegend), CD25 BUV421 (clone BC96, 
BioLegend), and CD69 PE (clone FN50, BioLegend) to deter-
mine NK cell (CD3-CD56+) activation by flow cytometry.
In vitro combination with CEA-TCB
The effect of combining FAP-IL2v with a T cell bispecific 
antibody that binds CEA on tumor cells and CD3 on T cells 
(CEA-TCB) was tested on MKN45 human gastric cancer cells 
co-cultured with PBMCs. Briefly, 30,000 MKN45 tumor cells 
were seeded into 96-well plates with 300,000 PBMCs (E:T 10:1) 
and incubated with increasing concentrations of FAP-IL2v in 
the presence or absence of 0.2 nM CEA-TCB. After 48 hours, 
cytotoxicity was determined by measuring LDH release as 
before. The release of Granzyme B, tumor necrosis factor, 
interferon γ, RANTES, IL-6, and IL-8 into the supernatant 
was determined by Cytokine Bead Array (BD Bioscience). 
Cells were stained with CD3 FITC (clone UCHT1, 
BioLegend), CD8 APC (clone SK1, BioLegend) and CD25 PE- 
Cy7 (clone BC-95, BioLegend) to determine CD8+ T cell (CD3 
+ CD8+) activation by flow cytometry.
Mouse xenograft and syngeneic models
Subcutaneous and orthotopic xenograft, syngeneic, and geneti-
cally engineered mice models were used to assess the in vivo 
efficacy of single-agent FAP-IL2v and combination therapies. 
This study was reviewed and approved by the Institutional 
Animal Care and Use Committee of the Preclinical 
Pharmacology Department, Roche Innovation Center Zurich, 
Schlieren, Switzerland, and performed in accordance with the 
animal research protocols approved by the local government 
(Kantonale Verwaltung Veterinäramt kant. Zürich, 
Switzerland; license ZH193/2014). All animals were handled 
according to guidelines of the Federation of European 
Laboratory Animal Science Associations, Gesellschaft für 
Versuchstierkunde/Society of Laboratory Animal Science (GV- 
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Solas) and the Tierschutzgesetz (TierSchG). Mice were main-
tained under specific-pathogen-free conditions with daily 
cycles of 12 hours light/darkness. Food and water were pro-
vided ad libitum. Continuous health monitoring was car-
ried out.
All mice were female and bred by Charles River 
Laboratories. Models comprised: human (hu) CD16- 
transgenic SCID mice IV inoculated with 3 × 106 A549- 
Fluc cells (non-small cell lung cancer xenograft lung model) 
or subcutaneously inoculated with 2 × 106 WSU-DLCL2 
cells (non-Hodgkin lymphoma model); huEGFR huCD16- 
transgenic C57BL/6 mice inoculated IV with 0.1 × 106 B16- 
huEGFR cells (syngeneic lung metastatic model); C57BL/6 
mice intrapancreatically inoculated with 1 × 105 Panc02-H7 
cells; CEA-transgenic C57BL/6 mice intrapancreatically 
inoculated with 1 × 105 Panc02-CEA cells (pancreatic syn-
geneic models); SCID beige mice; and BALB-neuT mice 
(19–21 weeks old; genetically engineered mouse model). 
BALB-neuT mice overexpress the rat HER2/neu oncogene 
and develop mammary hyperplasia within the first month 
of life, which progresses to aggressive carcinomas in all the 
10 mammary glands. Up to 10 mammary tumors can be 
found at week 22–24.
Mice were randomized and therapy started when evidence 
of tumor growth was visible in the target organ of sacrificed 
scout animals (days indicated in figure legends). All treat-
ments were administered IV unless indicated otherwise. The 
termination criteria for euthanizing animals were sickness 
with locomotion impairment. Median overall survival was 
defined as the experimental day by which 50% of animals 
had been sacrificed. Kaplan-Meier survival curves and the 
pairwise log-rank test were used to compare survival 
between animals.
Biodistribution and SPECT/CT imaging in mice
Fully immunocompetent BALB/c mice bearing orthotopic 
Renca tumors (n = 3 per group) were injected IV with tracer 
amounts (0.3 µg) of 111In-labeled antibodies FAP-IgG (4B9 
IgG), FAP-IL2v, FAP-IL2wt, and untargeted-IL2v (DP47- 
IL2v) along with 25 µg of corresponding unlabeled antibodies. 
SPECT/CT and terminal biodistribution studies were con-
ducted 3 days after antibody injection. In addition, SPECT/ 
CT images were acquired in CD-1 and C57BL/6 mice at 4, 24, 
and 72 hours at different FAP-IL2v dose levels (0.1, 0.3, and 
1.0 mg/kg) to determine whole-body tissue pharmacokinetics 
and the impact of IL-2R sink.
Mice were anesthetized (2% isoflurane/O2) and placed in 
prone position in the SPECT/CT scanner (U-SPECT-II, 
MILabs). SPECT images were acquired over 60 minutes using 
a 1.0-mm-diameter pinhole mouse collimator tube (3–4 frames 
of 15 minutes, 99 bed-positions per frame) followed by a CT 
scan (615 µA, 65 kV). Scans were reconstructed with MILabs 
reconstruction software. Mice were euthanized (CO2/O2 
asphyxiation) immediately after the last SPECT/CT scan and 
relevant tissues were dissected. The radioactivity concentration 
in the tissues was determined and uptake (%ID/g) was calcu-
lated. Unpaired t-tests were used to compare groups.
Imaging in rhesus monkey with breast carcinoma
The PET/CT procedure is described in detail in the supple-
ment. All studies involving this animal were approved by the 
Wake Forest University Institutional Animal Care and Use 
Committee and conducted in accordance with the US Animal 
Welfare Act and the Department of Health and Human 
Services regulations (Office of Laboratory Animal Welfare 
assurance number #A-3391-01). Wake Forest University is 
accredited by the Association for the Assessment and 
Accreditation of Laboratory Animal Care. This rhesus monkey 
was provided with appropriate veterinary care and social and 
environmental enrichment. Briefly, an 11-year-old rhesus 
monkey with confirmed spontaneously occurring invasive duc-
tal carcinoma with vascular invasion was treated with 0.5 mg/ 
kg of FAP-IL2v mixed with tracer amounts of FAP-IL2v radi-
olabeled with zirconium-89 (89Zr) as previously described.46 
PET scans were conducted on the day of administration and 
3 days (67 hours) and 6 days (154 hours) after injection. On- 
treatment tumor biopsy for assessment of immune cell infiltra-
tion was performed on Day 3 following the PET scan.
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ADCC, antibody-dependent cellular cytotoxicity; AICD, activation- 
induced cell death; CEA, Carcinoembryonic antigen; CEA-IL2v, 
Cergutuzumab amunaleukin; CT, Computed tomography; E:T, effector- 
to-target cell ratio; FAP, fibroblast activation protein α; FAP-IL2v, simlu-
kafusp alfa; FcRn, neonatal Fc receptor; IL-2, Interleukin-2; IL-2R, IL-2 
receptor; IL2v, IL-2 variant; IV, intravenously; LDH, lactate dehydrogen-
ase; NK, natural killer; PBMC, peripheral blood mononuclear cells; PD-1, 
programmed cell death protein 1; PD-L1, programmed death-ligand 1; 
PET, positron-emission tomography; SCID, severe combined immunode-
ficiency; SPECT, single-photon emission computed tomography; TDCC, 
T cell-dependent cellular cytotoxicity; Tregs, regulatory T cells; wt, wild- 
type.
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